Press Release

ONA Therapeutics Wins Biosuccess Award for its Growth as a Spin-Off

CataloniaBio & HealthTech has recognised ONA Therapeutics with the Biosuccess award 2021 for its consolidation, investment attraction and growth as a spin-off. The event took place during the UnConference, the annual day of debate on the future of healthcare solutions promoted by CataloniaBio & HealthTech.

ONA Therapeutics S.L. is a biotechnology company specializing in the discovery and development of new biological therapies aimed at metastasis initiating cells and lipid metabolism. Founded in 2019 by Valerie Vanhooren and Salvador Aznar-Benitah, it is a spin-off of the Catalan Institution for Research and Advanced Studies (ICREA) and the Barcelona Institute for Research in Biomedicine (IRB Barcelona). A year later, in 2020, ONA closed a series A funding round of 30 million euros, the largest round ever achieved by a company in preclinical stage in Spain, and one of the largest in Europe during 2020. This funding will allow ONA to complete preclinical development and initiate the first clinical studies in advanced cancer patients with its leading candidate. The Biosuccess award adds to other recent recognitions such as being named by Fierce Biotech one of the most promising biotechnology companies of 2020 and being among the eight finalists for the Nature Spinoff 2021 award.

Valerie Vanhooren, co-founder and CEO of ONA Therapeutics, about the CataloniaBio & HealthTech Bio-Success Award said, “You don’t know the energy it gives us to receive this recognition.” She highlighted the internationalization of the Catalan biotechnology sector and claimed that “in the sector we must stop being humble. Five years ago, when I arrived in Barcelona, in Catalonia, I found excellent science, capital and specialist investors, exceptional professionals and a strong biotechnology community.”

About Ona Therapeutics
Ona Therapeutics, with headquarters in the Barcelona Science Park (PCB), Barcelona, Spain, is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and
Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine. www.ona-therapeutics.com

Ona Therapeutics
Privacy Overview
ONA THERAPEUTICS, SL obtains personal data through the contact forms of the web, from those who submit any questions, requests and / or comments.
In accordance with current regulations on Data Protection, specifically, Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, personal data provided to ONA THERAPEUTICS, SL through this web portal will become part of its information systems that comply with the security measures required in order to guarantee the confidentiality, integrity, security and information retrieval.
The purposes for which these data are collected are those of being able to respond to your queries regarding the services we offer. In addition, of the timely response to your queries, we may, if you authorize us to do so, send you information electronically.
Your data will be kept for the period that you are registered to receive the requested information, being your revocable consent, it may be withdrawn at any time through the link that accompanies each shipment to communicate your WITHDRAWN or through an email to the address info@ona-therapeutics.com. From that moment, you will no longer receive any communication from us.
We will not proceed with the communication or transfer of your data, in any case, unless a public body requires it in accordance with the Law and those in charge of treatment that provide services related to our information systems.
You have the right to obtain confirmation about whether we are treating your personal data, therefore, you have the right to access your personal data (Right of Access), you have the right to rectify inaccurate data (Right of Rectification) or to request its deletion (Right to deletion) when the data is no longer necessary, you have the right to exercise your opposition to the processing of data (Right of opposition), to exercise your right to the limitation of the processing, as well as you will have the right to the portability of your data, if it is the case. All this by writing to our access addresses in Calle Baldiri Reixach 10, Barcelona, ​​Spain or via email info@ona-therapeutics.com in accordance with the procedure of articles 15 to 23 of Regulation (EU) 2016 / 679 of the European Parliament and of the Council, of April 27, 2016.
ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its alteration, loss, treatment or unauthorized access, taking into account the state of the technology, the nature of the stored data and the risks to which they are exposed, already come from human action or from the physical or natural environment.
To protect the privacy of the USERS, it is prohibited to send any information regarding their ideology, religion, beliefs, racial origin, health, and sexual life through our forms.
Likewise, we inform you that, under no circumstances will automated individual decisions or profiling be made.